Menu Search
Equities

Hikma Pharmaceuticals PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HIK:LSE

Hikma Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,210.00
  • Today's Change-39.00 / -3.12%
  • Shares traded1.36m
  • 1 Year change-43.67%
  • Beta0.9531
Data delayed at least 20 minutes, as of Mar 05 2026 14:57 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Hikma Pharmaceuticals PLC grew revenues 6.12% from 3.16bn to 3.35bn while net income improved 35.10% from 359.00m to 485.00m.
Gross margin43.51%
Net profit margin14.63%
Operating margin18.69%
Return on assets9.07%
Return on equity19.78%
Return on investment13.34%
More ▼

Cash flow in USDView more

In 2025, Hikma Pharmaceuticals PLC increased its cash reserves by 15.43%, or 29.00m. The company earned 436.00m from its operations for a Cash Flow Margin of 13.02%. In addition the company used 388.00m on investing activities and also paid 25.00m in financing cash flows.
Cash flow per share2.36
Price/Cash flow per share5.25
Book value per share8.74
Tangible book value per share4.80
More ▼

Balance sheet in USDView more

Hikma Pharmaceuticals PLC has a Debt to Total Capital ratio of 38.10%, a higher figure than the previous year's 28.27%.
Current ratio1.82
Quick ratio1.06
Total debt/total equity0.6186
Total debt/total capital0.381
More ▼

Growth rates in USD

Year on year, growth in dividends per share fell -37.59% while earnings per share excluding extraordinary items rose 35.59%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.63%
Div growth rate (5 year)-1.07%
Payout ratio (TTM)16.49%
EPS growth(5 years)3.76
EPS (TTM) vs
TTM 1 year ago		35.63
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.